Compare iShares MSCI Indonesia ETF (EIDO) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs ResMed Inc. — how do they compare? iShares MSCI Indonesia ETF trades at $11.84 (market cap $409.22M), while ResMed Inc. trades at $229.48 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 77.9× iShares MSCI Indonesia ETF's market cap, and ResMed Inc. pays a 1.16% dividend while iShares MSCI Indonesia ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Indonesia ETF for 75 Days and ResMed Inc. for 51 Days on average.
| EIDO | RMD | |
|---|---|---|
Market Cap | $409.22M | $31.89B |
Volume | 879,527 | 618,314 |
52-Week High | $19.22 | $277.88 |
52-Week Low | $10.80 | $182.82 |
Typical Hold Time | 75 Days | 51 Days |
Sector | — | Health |
Enterprise Value | — | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EIDO (iShares MSCI Indonesia ETF) trades at $11.82, down 0.34% with bearish technical signals from moving averages. The ETF faces weak price action despite attractive valuation metrics, with technical indicators showing mixed signals including a neutral RSI but bearish ADX readings. Trading volume declined 21% below average, indicating reduced investor interest.
The outlook remains cautious given persistent technical downtrend and Indonesia's limited benefit from commodity gains. While valuation appears attractive at 8.7x P/E, the 44% financials weighting and modest 5.9% long-term EPS growth constrain upside potential. Key risks include sector concentration and regional capital outflows from Asian equities.
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
